TitleAssociate Professor
InstitutionMD Anderson
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cole AJ, Panesso-G?mez S, Shah JS, Ebai T, Jiang Q, Gumusoglu-Acar E, Bello MG, Vlad A, Modugno F, Edwards RP, Buckanovich RJ. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy. Clin Cancer Res. 2023 05 15; 29(10):1969-1983. PMID: 36795892; PMCID: PMC10192102.
      Citations: 1     Fields:    Translation:HumansCells
    2. Shah JS, Gard GB, Yang J, Maidens J, Valmadre S, Soon PS, Marsh DJ. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer. Gynecol Oncol. 2018 01; 148(1):181-188. PMID: 29132874.
    3. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616.
      Citations: 17     Fields:    Translation:Humans
    4. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9. PMID: 25257030; PMCID: PMC4840190.
      Citations: 80     Fields:    Translation:Humans
    5. Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34. PMID: 25254936; PMCID: PMC4687395.
      Citations: 26     Fields:    Translation:Humans
    6. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9. PMID: 25023650; PMCID: PMC4372187.
      Citations: 48     Fields:    Translation:Humans
    7. Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51. PMID: 25174656.
      Citations: 8     Fields:    Translation:Humans
    8. Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, Black PC, J?ger W. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol. 2013 Oct; 190(4):1404-9. PMID: 23500642; PMCID: PMC3805942.
      Citations: 17     Fields:    Translation:HumansCells
    9. Shah JB, Kamat AM. Strategies for optimizing bacillus Calmette-Gu?rin. Urol Clin North Am. 2013 May; 40(2):211-8. PMID: 23540779.
      Citations: 4     Fields:    Translation:Humans
    10. DeGraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, Liebert M, Wu XR, Taylor JA, Translational Science Working Group of the Bladder Advocacy Network Think Tank. Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther. 2013 Feb; 12(2):121-30. PMID: 23269072.
      Citations: 18     Fields:    Translation:HumansAnimals
    11. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ. 2013 Mar; 20(3):382-95. PMID: 23175184; PMCID: PMC3569985.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    12. Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat E, Dinney C, Otto W, Shah J, Witjes JA, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladd, Burger M, Th?rof J. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):36-44. PMID: 22981672.
      Citations: 51     Fields:    Translation:Humans
    13. Bachir BG, Shariat SF, Zlotta A, Svatek R, Black PC, Shah JB, Kassouf W, Bladder Cancer Think Tank (Bladder Cancer Advocacy Network), Canadian Bladder Cancer Network (Bladder Cancer Canada). Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. 2013 Mar; 111(3):419-26. PMID: 22928764.
      Citations: 2     Fields:    Translation:Humans
    14. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13. PMID: 22564397; PMCID: PMC3815632.
      Citations: 49     Fields:    Translation:Humans
    15. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206. PMID: 22253920; PMCID: PMC3254658.
      Citations: 38     Fields:    Translation:HumansCells
    16. Davis JW, Shah JB, Achim M. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int. 2011 Sep; 108(6 Pt 2):993-8. PMID: 21917102.
      Citations: 9     Fields:    Translation:Humans
    17. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res. 2011 May 01; 17(9):2608-12. PMID: 21415213.
      Citations: 52     Fields:    Translation:Humans
    18. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther. 2010 Nov 01; 10(9):885-92. PMID: 20814238; PMCID: PMC3230293.
      Citations: 17     Fields:    Translation:HumansCells
    19. Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special? Cancer. 2011 Mar 01; 117(5):882-3. PMID: 20960505.
      Citations:    Fields:    Translation:Humans
    20. Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 01; 116(19):4513-9. PMID: 20572047.
      Citations: 17     Fields:    Translation:Humans
    21. Shah JB, Margulis V. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther. 2010 Jun; 10(6):837-42. PMID: 20553209.
      Citations: 2     Fields:    Translation:Humans
    22. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44. PMID: 20012924; PMCID: PMC5915353.
      Citations: 176     Fields:    Translation:HumansCells
    23. Shah JB, Margulis V. Clinical trials: nationally representative data in urology. Nat Rev Urol. 2009 Jul; 6(7):354-5. PMID: 19578349.
      Citations:    Fields:    Translation:Humans
    24. Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol. 2009 Nov-Dec; 27(6):585-91. PMID: 19162510.
      Citations: 7     Fields:    Translation:HumansAnimals
    25. Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV, CaPSURE Investigators. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol. 2008 Jan; 179(1):136-40. PMID: 17997437.
      Citations: 4     Fields:    Translation:Humans
    26. Shah JB, Whitman C, Lee M, Gupta M. Water under the bridge: 5-year outcomes after percutaneous ablation of obstructing parapelvic renal cysts. J Endourol. 2007 Oct; 21(10):1167-70. PMID: 17949318.
      Citations: 5     Fields:    Translation:Humans
    27. Mitchell RE, Shah JB, Desai M, Mansukhani MM, Olsson CA, Benson MC, McKiernan JM. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology. 2007 Oct; 70(4):706-10. PMID: 17707892.
      Citations: 5     Fields:    Translation:Humans
    28. Shah JB, Badalato GM, McKiernan JM. New treatments for superficial bladder cancer. Curr Oncol Rep. 2006 May; 8(3):201-5. PMID: 16618384.
      Citations:    Fields:    Translation:HumansAnimals
    29. Mitchell RE, Desai M, Shah JB, Olsson CA, Benson MC, McKiernan JM. Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J Urol. 2006 May; 175(5):1663-7; discussion 1667. PMID: 16600724.
      Citations: 2     Fields:    Translation:Humans
    30. Mitchell RE, Shah JB, Olsson CA, Benson MC, McKiernan JM. Does year of radical prostatectomy independently predict outcome in prostate cancer? Urology. 2006 Feb; 67(2):368-72. PMID: 16461087.
      Citations: 1     Fields:    Translation:Humans
    31. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005 Sep; 174(3):827-34. PMID: 16093964.
      Citations: 45     Fields:    Translation:Humans
    32. Shah JB, Reese AC, McKiernan JM, Benson MC. PSA updated: still relevant in the new millennium? Eur Urol. 2005 Apr; 47(4):427-32. PMID: 15774237.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    33. Shah JB, McKiernan JM. Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol. 2004 Sep; 14(5):287-93. PMID: 15300149.
      Citations: 5     Fields:    Translation:Humans
    34. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus.
    35. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy. European Urology.
    36. Epidemiology and risk factors of upper tract urothelial carcinoma (UTUC). 393-408.
    37. Controversies regarding postvasectomy management. 114-118.
    38. Risk of hospitalisation after primary treatment for prostate cancer. BJU International.
    39. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy. Urologic Oncology: Seminars and Original Investigations. 34:59.e1-59.e8.
    40. Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. Urologic Oncology: Seminars and Original Investigations. 34:120.e17-120.e21.
    41. The Future of Enhanced Recovery for Radical Cystectomy. Urology. 96:62-68.
    42. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?. Journal of Urology.
    43. Annals of Surgical Oncology. 1-5.
    44. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World Journal of Urology.
    45. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International.
    46. Managing the vasectomy patient. Contemporary Urology. 18:40-49.
    SHAH's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (173)
    Co-Authors (28)
    Similar People (60)
    Same Department Expand Description